Silence Therapeutics (SLN) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLN shares.
View SLN analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1 year target prices for Silence Therapeutics' stock. Their SLN share price forecasts range from $20.00 to $80.00. On average, they anticipate the company's stock price to reach $44.75 in the next year. This suggests a possible upside of 683.7% from the stock's current price.
View analysts price targets for SLN or view top-rated stocks among Wall Street analysts.

Silence Therapeutics' stock was trading at $15.25 at the beginning of the year. Since then, SLN shares have decreased by 62.6% and is now trading at $5.71.
View the best growth stocks for 2023 here.

Silence Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 22,400 shares, a decrease of 36.7% from the April 30th total of 35,400 shares. Based on an average daily volume of 74,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are sold short.
View Silence Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SLN earnings forecast.

Silence Therapeutics plc (NASDAQ:SLN) posted its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by $0.91. The firm earned $5.59 million during the quarter, compared to analyst estimates of $36.30 million. Silence Therapeutics had a negative trailing twelve-month return on equity of 254.24% and a negative net margin of 185.71%.

Silence Therapeutics trades on the NASDAQ under the ticker symbol "SLN."

Silence Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include AXA S.A. (1.73%) and Schonfeld Strategic Advisors LLC (0.14%).

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SLN stock can currently be purchased for approximately $5.71.

Silence Therapeutics (NASDAQ:SLN) has a market capitalization of $170.90 million and generates $21.65 million in revenue each year. The company earns $-50,080,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

The company employs 105 workers across the globe.

Silence Therapeutics' mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at 44-0-20-3457-6900.